Tarsus Pharmaceuticals(US:TARS)2025-11-04 21:08Financial Performance - XDEMVY net sales for Q3 2025 were approximately $119 million, representing a year-over-year increase of approximately 147%[1] - Product sales for Q3 2025 reached $118.7 million, a significant increase of 146.5% compared to $48.1 million in Q3 2024[20] - Total revenues for the nine months ended September 30, 2025, were $299.7 million, up from $116.5 million in the same period of 2024, representing a growth of 156.5%[20] - Year-to-date product sales reached $299.7 million, compared to $113.7 million for the same period in 2024, driven by approximately 266,000 bottles of XDEMVY delivered[6] Expenses - Research and development (R&D) expenses for Q3 2025 were $16.3 million, up from $12.1 million in Q3 2024, primarily due to increased program expenses and personnel costs[6] - Selling, general and administrative (SG&A) expenses for Q3 2025 were $108.6 million, compared to $57.9 million in Q3 2024, driven by increased commercial and marketing costs[6] - Research and development expenses increased to $16.3 million in Q3 2025, compared to $12.1 million in Q3 2024, reflecting a rise of 34.5%[20] - Selling, general and administrative expenses surged to $108.6 million in Q3 2025, up from $57.9 million in Q3 2024, marking an increase of 87.5%[20] Net Loss - The net loss for Q3 2025 was $12.6 million, an improvement from a net loss of $23.4 million in Q3 2024[6] - The net loss for Q3 2025 was $12.6 million, an improvement from a net loss of $23.4 million in Q3 2024[20] Cash Position - As of September 30, 2025, Tarsus had a cash position of $401.8 million[6] - Cash and cash equivalents increased to $112.7 million as of September 30, 2025, compared to $94.8 million at the end of 2024, showing a growth of 18.5%[22] Assets and Liabilities - Total assets rose to $534.6 million as of September 30, 2025, up from $377.0 million at the end of 2024, indicating an increase of 42.0%[22] - Total liabilities increased to $199.5 million as of September 30, 2025, compared to $152.5 million at the end of 2024, reflecting a rise of 30.8%[22] - The accumulated deficit as of September 30, 2025, was $418.3 million, compared to $360.2 million at the end of 2024[22] Product Delivery - More than 103,000 bottles of XDEMVY were delivered to patients in Q3 2025, compared to over 41,400 bottles in the same period in 2024[6] Future Plans - Tarsus plans to initiate a Phase 2 study of TP-04 for ocular rosacea in December 2025, with topline data expected by year-end 2026[3] - Tarsus is also advancing TP-05, an oral tablet for the potential prevention of Lyme disease, with a planned study in 2026[3] Shares Outstanding - The weighted-average shares outstanding increased to 42.6 million in Q3 2025 from 38.4 million in Q3 2024[20]